Industry reports
Editor highlights

Pathology

Summary

Table of Contents

  • Publication date: September 2012
Keywords : prostate cancer, lymphoma, breast cancer

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Prostate Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus ar...

More »

Search ReportLinker

The Largest Collection of Market Research Reports

» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides

From +200,000 authoritative sources

Talk to Jordan

+1 917 267 7886

Send Your Request

Pathology Industry : Latest Reports

Trypanosomiasis - Pipeline Review, H2 2013

Trypanosomiasis - Pipeline Review, H2 2013

  • $ 2 000
  • Company report
  • December 2013
  • by Global Markets Direct

Trypanosomiasis - Pipeline Review, H2 2013 Summary Global Markets Direct's, 'Trypanosomiasis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides ...

Chronic Urticaria Or Hives - Pipeline Review, H2 2013

Chronic Urticaria Or Hives - Pipeline Review, H2 2013

  • $ 2 000
  • Company report
  • December 2013
  • by Global Markets Direct

Chronic Urticaria Or Hives - Pipeline Review, H2 2013 Summary Global Markets Direct's, 'Chronic Urticaria Or Hives - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. ...

Hemoglobinopathies - Pipeline Review, H2 2013

Hemoglobinopathies - Pipeline Review, H2 2013

  • $ 2 000
  • Company report
  • December 2013
  • by Global Markets Direct

Hemoglobinopathies - Pipeline Review, H2 2013 Summary Global Markets Direct's, 'Hemoglobinopathies - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report ...

Rubella - Pipeline Review, H2 2013

December 2013 $ 2 000

Pathology Industry : Latest Downloads

Company Report: Cancer for Year 2014

  • Company report
  • April 2014
  • 2 pages

... Personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class ...

Company Report: Pathology for Year 2014

  • Company report
  • April 2014
  • 7 pages

Company Report: Pathology for Year 2014

  • Company report
  • April 2014
  • 6 pages

... For ampyra in stroke, the adaptive design of the phase 2/3 trial should allow acorda to take an interim look at efficacy as measured by 2-min walk distance as well as a scaled efficacy measurement similar ...


Related Market Segments :

Cancer
Prostate Cancer
Lymphoma
Breast Cancer

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.